

BCL-XL Antibody

Catalog No: #21061

Package Size: #21061-1 50ul #21061-2 100ul

Orders: order@signalwayantibody.comSupport: tech@signalwayantibody.com

Description


Product Name	BCL-XL Antibody
Host Species	Rabbit
Clonality	Polyclonal
Purification	Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific peptide.
Applications	WB
Species Reactivity	Human;Mouse;Rat
Specificity	The antibody detects endogenous level of total BCL-XL protein.
Immunogen Type	Peptide-KLH
Immunogen Description	Peptide sequence around aa.60~64 (A-D-S-P-A) derived from human BCL-XL .
Conjugates	Unconjugated
Target Name	BCL-XL
Other Names	Apoptosis regulator Bcl-X
Accession No.	Swiss-Prot: Q07817NCBI Protein: NP_612815.1
Concentration	1.0mg/ml
Formulation	Supplied at 1.0mg/mL in phosphate buffered saline (without Mg ²⁺ and Ca ²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Storage	Store at -20°C for long term preservation (recommended). Store at 4°C for short term use.

Application Details

Predicted MW: 30kd

Western blotting: 1:500~1:1000

Images



Western blot analysis of extracts from 293 and HeLa cells using BCL-XL(Ab-62) antibody #21061.

Background

Potent inhibitor of cell death. Isoform Bcl-X(L) anti-apoptotic activity is inhibited by association with SIVA isoform 1. Inhibits activation of caspases By similarity. Appears to regulate cell death by blocking the voltage-dependent anion channel (VDAC) by binding to it and preventing the release of the caspase activator, cytochrome c, from the mitochondrial membrane. The Bcl-X(S) isoform promotes apoptosis.

Basu A, et.al.(2003) Mar 13; 538(1-3): 41-7

Cheng E.H.-Y. et.al. (1996) Nature 379:554-556.

Sattler M. et.al. (1997), Science 275:983-986.

Muchmore S.W.et.al (1996).Nature 381:335-341

Yu J., Zhang L. Mol. (2001)Cell 7:673-682

Published Papers

el at., Autophagy regulates the degeneration of the auditory cortex through the AMPK-mTOR-ULK1 signaling pathway.In Int J Mol Med. On 2018 Apr by Yuan J, Zhao X et al..PMID: 29344647, , (2018)

[PMID:29344647](#)

el at., Mitochondria-targeted antioxidant therapy for an animal model of PCOS-IR. In Int J Mol Med on 2019 Jan by Ding Y, Jiang Z, et al..PMID:30431108, , (2019)

[PMID:30431108](#)

el at., Mitochondria-targeted antioxidant therapy for an animal model of PCOS-IR. In Int J Mol Med on 2019 Jan by Yu Ding, Zhaochang Jiang, et al..PMID: 30431108, , (2019)

[PMID:30431108](#)

el at., Mitochondria-targeted antioxidant therapy for an animal model of PCOS-IR. In Int J Mol Med on 2019 Jan by Ding Y, Jiang Z, et al..PMID:30431108, , (2019)

[PMID:30431108](#)

el at., PIWI-Interacting RNA-004800 Is Regulated by S1P Receptor Signaling Pathway to Keep Myeloma Cell Survival.In Front Oncol on 2020 Apr 15 by Ma H, Wang H, et al..PMID: 32351883, , (2020)

[PMID:32351883](#)

el at., Anticancer effects of sodium butyrate on hepatocellular carcinoma cells in vitro. In Int J Mol Med on 2013 Apr by Hong-Gang Wang, Xiao-Dan Huang, et al..PMID:

23440283, , (2013)

[PMID:23440283](#)

el at., Suppression of chronic lymphocytic leukemia progression by CXCR4 inhibitor WZ811.In Am J Transl Res. On 2016 Sep 15 by SH Li, WC Dong et al..PMID:27725861, , (2016)

[PMID:27725861](#)

el at., miR-137 and miR-197 induce apoptosis and suppress tumorigenicity by targeting MCL-1 in multiple myeloma.In Clin Cancer Res on 2015 May 15 by Yijun Yang , Fei Li et al..PMID:25724519 , , (2015)

[PMID:25724519](#)

el at., The antitumor activity of a novel GCN2 inhibitor in head and neck squamous cell carcinoma cell linesInTransl OncolOn 2023 JanbyJeongjae Lee, Bhumsuk Keam et al..PMID:36436443, , (2023)

[PMID:36436443](#)

Note: This product is for in vitro research use only and is not intended for use in humans or animals.